Application of Bremelinan in preparation of medicine for treating cerebral arterial thrombosis
Through Bremerondan, the MC1R and MC4R receptors are activated, and the problem of lack of effective neuroprotective agents in the prior art is solved, and effective treatment of ischemic stroke is achieved, which significantly reduces the area of cerebral infarction and improves cerebral blood flow. Improve cognitive function.
Patent Information
- Application Number
- CN202411223370.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The lack of effective neuroprotective agents in the prior art to treat ischemic stroke, resulting in a lack of clear therapeutic effects on symptomatic support and improvement of cerebral blood supply.
Bremelanotide is used as a drug component to activate MC1R and MC4R receptors, exert anti-inflammatory, antioxidant, increase cerebral blood flow and neuroprotection, improve cognitive function, and is used to prepare and treat ischemic brain Stroke medication.
Bremerondan significantly reduces the area of cerebral infarction, improves the improvement rate of cerebral infarction, and improves behavioral dysfunction, which proves that it has a dose-related neuroprotective effect as a drug for the treatment of ischemic stroke.
Smart Images

Figure CN119074890A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and particularly relates to the use of bremelanotide in preparing a drug for treating ischemic stroke. Background Art
[0002] Stroke, also known as apoplexy or cerebrovascular accident, is a group of acute cerebrovascular diseases with sudden onset, caused by local cerebral blood circulation disorders and characterized by focal neurological deficits. It has become one of the three major death diseases in the world due to its high morbidity, high mortality, high disability rate and high recurrence rate. Among them, ischemic stroke, also known as cerebral infarction, refers to brain tissue necrosis caused by insufficient blood supply to the brain due to stenosis or occlusion of the cerebral blood supply artery. Ischemic stroke accounts for 70-80% of all strokes. The pathogenesis of ischemic stroke is relatively complex and involves multiple pathological and physiological processes, such as thrombosis, embolism, and hypoperfusion. Among them, thrombosis is the most common cause, mainly caused by atherosclerosis; embolism is caused by cardiogenic or arterial emboli blocking the brain's blood supply arteries; hypoperfusion is caused by low blood pressure or severe stenosis of blood vessels, resulting in reduced blood flow to the brain.
[0003] Ischemic stroke is caused by loss of blood supply to part of the brain, triggering the ischemic cascade. The ischemic cascade is a series of biochemical reactions that are set in motion in the brain and other aerobic tissues within seconds to minutes of ischemia. Most ischemic neuronal death is due to activation of chemicals produced during and after ischemia. The ischemic cascade usually lasts two to three hours but may continue for days even after blood flow is restored.
[0004] The ischemic cascade can usually have the following characteristics: insufficient blood supply leads to tissue hypoxia, which causes neurons to be unable to normally produce ATP to provide energy. The ion transport pump of ATP fails, causing cell depolarization, which makes calcium (Ca 2+ ) flows into the cell. Ion pumps can no longer transport calcium ions out of the cell, resulting in excessive calcium levels inside the cell. The presence of calcium triggers the release of the excitatory amino acid neurotransmitter glutamate. Glutamate stimulates AMPA receptors and Ca 2+Permeability NMDA receptors, these receptors open to allow more calcium to enter the cell. Excess calcium ions entering the cell can cause the cell to become overexcited and produce harmful chemicals such as free radicals, reactive oxygen species, and calcium-dependent enzymes, a process called excitotoxicity. Calcium can also cause the release of more glutamate. If the cell dies, it releases glutamate and toxic chemicals into the surrounding environment. The toxins poison nearby neurons, and the glutamate causes these neurons to become overexcited. If the brain is reperfused, many factors can cause reperfusion injury. The inflammatory response begins to increase, and phagocytes eat up damaged but still viable tissue. Harmful chemicals damage the blood-brain barrier. Large molecules in the blood vessels (such as albumin) pass through the damaged blood-brain barrier. These large molecules use osmosis to draw water into the brain tissue, causing brain edema, which leads to compression and further damage to the brain tissue.
[0005] At present, the strategies for the treatment of ischemic stroke mainly include two aspects: one is to restore brain reperfusion and improve cerebral blood supply; the other is to block the injury cascade reaction and prevent neuronal damage. In view of the complexity of the pathological mechanism of ischemic stroke, there is no specific drug for clinical use at present, and only symptomatic supportive treatment drugs can be used, and drugs for neuroprotection and improving cerebral vascular circulation are used. In addition to the definite efficacy of ultra-early thrombolysis, there is no neuroprotective agent that has been proven to have a definite effect by evidence-based medicine.
[0006] Bremelanotide, also known as pumelatide and PT141, is a good agonist of MC1R and MC4R melanocortin receptors. MC4R is a membrane protein of 332 amino acids. Extensive localization studies in the rodent brain have shown that MC4R mRNA is expressed in multiple brain regions, including the cortex, brainstem, thalamus, hypothalamus, hippocampus and spinal cord. MC4R is also known as neural MCR, but there are no reports on the use of Bremelanotide in the treatment of ischemic stroke. Summary of the invention
[0007] The present invention aims at the problems existing in the prior art and provides the use of bremelanotide in preparing a drug for treating ischemic stroke.
[0008] Use of bremelanotide in preparing a drug for preventing and / or treating ischemic stroke.
[0009] Preferably, bremelanotide is used in the preparation of a drug for improving neurological impairment.
[0010] Preferably, bremelanotide is used in the preparation of a drug for reducing the area of cerebral infarction.
[0011] Preferably, bremelanotide is used in the preparation of a drug for improving cerebral blood flow in ischemic stroke.
[0012] Preferably, bremelanotide is the only active ingredient in the medicament.
[0013] Preferably, the drug further comprises a pharmaceutically acceptable excipient.
[0014] Preferably, the auxiliary materials include one or more of surfactants, buffer substances, disintegrants, binders, fillers, lubricants, solubilizers, flavoring agents and colorants.
[0015] Preferably, the dosage form of the drug includes an oral dosage form and a parenteral dosage form.
[0016] Preferably, the oral dosage form is a tablet, capsule, granule, granule, pill, oral liquid preparation or lyophilized powder injection.
[0017] Preferably, the non-intestinal administration dosage form is an injection dosage form, a respiratory tract administration dosage form, a skin administration dosage form, a mucosal administration dosage form or a cavity administration dosage form.
[0018] The present invention provides a new use of bremelanotide in the preparation of a drug for treating ischemic stroke. Its mechanism of action is:
[0019] (1) Anti-inflammatory: Bremelanotide significantly reduces the production of inflammatory factors by activating MC1R and MC4R. In addition to being expressed in keratinocytes and melanocytes, MC1R is also expressed in macrophages, monocytes, lymphocytes, neutrophils, and dendritic cells. It can participate in regulating the inflammatory process in the brain and has an anti-inflammatory effect.
[0020] (2) Antioxidation: MC4R agonists can promote antioxidant defense and reduce mitochondrial damage, preventing ethanol-induced increase in reactive oxygen species (ROS), dysregulation of cytoplasmic calcium homeostasis, and loss of mitochondrial potential.
[0021] (3) Increase cerebral blood flow: Bremelanotide increases the density and size of blood vessels in the cerebral cortex of stroke rats, enhances collateral blood flow, restores vascular function and improves cerebral blood flow.
[0022] (4) Protecting neurons: Bremelanotide significantly increases the number of neurons around the infarct focus, protects the neurons of living tissue, and exerts a neuroprotective effect.
[0023] (5) Improve cognitive function: Activating melanocortin receptors can significantly improve cognitive function.
[0024] Compared with the prior art, the present invention has the following beneficial effects:
[0025] The present invention provides a new drug use of bremelanotide, namely, the use of bremelanotide in the preparation of a drug for treating ischemic stroke. Studies have found that bremelanotide can effectively improve behavioral dysfunction, significantly reduce the area of cerebral infarction, and improve the improvement rate of cerebral infarction, and show a dose-related effect, indicating that bremelanotide has a neuroprotective effect on ischemic stroke, confirming that bremelanotide can be used as a drug for treating ischemic stroke. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 Doppler cerebral blood flow observation diagram of rats in each group 10 minutes after surgery.
[0027] Figure 2 Doppler cerebral blood flow observation diagram of rats in each group 24 hours after surgery.
[0028] Figure 3 Doppler cerebral blood flow observation diagram of rats in each group 48 hours after surgery.
[0029] Figure 4 TTC staining images of brain sections of rats in the sham operation group.
[0030] Figure 5 TTC staining images of brain sections of rats in the model group.
[0031] Figure 6 This is the TTC staining image of the brain sections of rats in the high-dose group of bremelanotide.
[0032] Figure 1-3 In the figure, from left to right, there are sham operation group, model group, high-dose bremelanotide group and low-dose bremelanotide group. DETAILED DESCRIPTION
[0033] It is worth noting that the raw materials used in the present invention are all common commercially available products.
[0034] Example Therapeutic effect of bremelanotide on stroke rats
[0035] 1. Experimental Materials
[0036] 1.1 Drugs: bremelanotide, peptide content 89%; isoflurane, batch number 2023110302, purchased from Shenzhen Ruiwode Life Science Technology Co., Ltd.; normal saline, batch number 123101601, purchased from Zhejiang Tianrui Pharmaceutical Co., Ltd.; 2,35-triphenyltetrazolium chloride (TTC), batch number BMX311, purity 98%, purchased from Bid Pharmaceuticals.
[0037] 1.2 Drug preparation: Weigh 13.5 mg of bremelanotide, add 8.01 mL of normal saline and mix evenly until the final volume is 8.01 mL. The drug concentration is 1.5 mg / mL, which is recorded as solution 1; take 2 mL of solution 1, add 4 mL of normal saline and mix evenly until the final volume is 6 mL. The final drug concentration is 0.5 mg / mL.
[0038] 1.3 Experimental animals: 40 SD rats, SPF grade male, weighing about 200-220g, purchased from Shanghai Slake Experimental Animal Co., Ltd., production license number SCXK (Shanghai) 2022-0004, adapted to the environment for 3-5 days, free food and water, feed purchased from Jiangsu Collaborative Pharmaceutical Bioengineering Co., Ltd., water was sterilized and filtered by high pressure sterilization. The environment of the animal room was maintained at a temperature of 20-25°C, a humidity of 40-70%, and 12h light and dark alternation. Animals were kept in 5 cages, and the bedding was changed twice a week (the bedding was corn cob bedding, purchased from Suzhou Daichuan Trading Co., Ltd.).
[0039] 2. Experimental methods:
[0040] 2.1 Grouping: SD rats were randomly divided into 4 groups, with 10 rats in each group, namely sham operation group, model group, low-dose bremelanotide group and high-dose bremelanotide group.
[0041] 2.2 Animal modeling: Except for the sham operation group, the experimental animals were anesthetized with isoflurane during the modeling process, and spontaneous breathing was maintained. They were fixed on the mouse board in the supine position, the hair was removed in the middle of the neck, and disinfected with 75% alcohol. A surgical incision was made in the middle of the ventral neck of the rat, and the muscles and fascia were separated along the inner edge of the sternocleidomastoid muscle, and the right common carotid artery, external carotid artery, and internal carotid artery were separated, and the vagus nerve was separated from them. The external carotid artery was ligated and cut, and a small bevel was cut at the ligation site of the external carotid artery with vascular scissors, and the proximal end of the external carotid artery was pulled until it was in a straight line with the internal carotid artery. The nylon suture (model L3200, purchased from Guangzhou Jialing Biotechnology Co., Ltd.) was slowly pushed through the right external carotid artery trunk incision toward the direction of the internal carotid artery entering the skull, with the common carotid artery bifurcation as a mark. When slight resistance was felt during the advancement, the middle cerebral artery was blocked. About 10 minutes after the obstruction, the Doppler blood flow meter was used to observe the blood flow in the rat brain to confirm that the model was successfully incorporated into the group, and the nylon suture was removed 1.5 hours after the obstruction to complete the ischemic stroke model.
[0042] 2.3 Administration: The subcutaneous injection dose of the low-dose bremelanotide group was 1 mg / kg, and the subcutaneous injection dose of the high-dose bremelanotide group was 3 mg / kg. The model group was given an equal amount of normal saline. Except for the sham operation group, each group was given the corresponding drug 15 minutes, 24 hours and 48 hours after modeling.
[0043] 2.4 Experimental indicator detection:
[0044] (1) Zea-Longa neurological function score: Zea-Longa scoring criteria: 0 points: no neurological deficit symptoms; 1 point: unable to fully extend the contralateral forelimb; 2 points: turning toward the hemiplegic side when walking; 3 points: leaning toward the hemiplegic side when walking; 4 points: unable to walk spontaneously and impaired consciousness.
[0045] (2) Balance beam test: Rats were trained for 2 consecutive days before modeling. The walking beam device consisted of a 1-meter-long horizontal beam with a flat surface 50 cm above the ground. The rats were placed at the other end of the beam to encourage them to cross the horizontal beam. The training was conducted three times a day. Each animal was tested on the balance beam 24 h and 48 h after modeling. The timer was 60 s and the time it took for the rat to cross the horizontal beam was recorded. The final result was the average of the three test results.
[0046] (3) Grip strength test: The grip strength was assessed by clamping the rat's tail and placing its forelimbs on a special pull rod assembly (grip dynamometer). The peak amount of force applied by the animal was displayed and recorded on a digital display. Each animal was tested three times at 24h and 48h after modeling surgery, and the final result was the average of the three test results.
[0047] (4) Rotarod test: Before modeling, rats were trained to adapt to the rotating rod at a constant speed of 18 rpm and 25 rpm. Rats that reached the standard of staying on the rotating spindle for 300 s were selected for further study. Each animal was subjected to a rotation test (30 rpm, 300 s) 24 h and 48 h after modeling surgery, and the falling time of each rat was recorded.
[0048] (5) Changes in cerebral blood flow: Doppler blood flowmetry was used to measure changes in cerebral blood flow in each animal 10 minutes, 24 hours, and 48 hours after modeling surgery.
[0049] (6) Brain volume and cerebral infarction area test: At the end of the experiment (52 h after modeling surgery), CO 2 All animals were euthanized by overdose inhalation, and the whole brain tissue was removed for brain volume measurement using the drainage method. Serial coronal sections of animals in each group were stained with TTC and photographed, and the infarct area was measured using Image-J software, and the infarct improvement rate was calculated.
[0050] The experimental data were expressed as Mean±SD and analyzed using IBM SPSS Statistics 21 software. p<0.05 was considered to be a significant difference, and p<0.01 was considered to be a very significant difference. GraphPad Prism 6 was used for plotting.
[0051] 3. Experimental results
[0052] 3.1 Zea-Longa neurological function score results: The results are shown in Table 1. 24 hours after surgery, the neurological function score of rats in the sham operation group was 0.00±0.00; the neurological function score of rats in the model group was 2.80±0.42. Compared with the sham operation group, there was a statistically significant difference (p<0.01); the neurological function score of rats in the high-dose bremelanotide group was 2.89±0.33; the neurological function score of rats in the low-dose bremelanotide group was 2.67±0.50.
[0053] 48 hours after surgery, the neurological function score of rats in the sham operation group was 0.00±0.00; the neurological function score of rats in the model group was 2.80±0.42. Compared with the sham operation group, there was a statistically significant difference (p<0.01); the neurological function score of rats in the high-dose bremelanotide group was 2.78±0.44; the neurological function score of rats in the low-dose bremelanotide group was 2.78±0.44.
[0054] Table 1 Effects of bremelanotide on neurological function scores in stroke rats (n=10)
[0055]
[0056] Note: ## Compared with the sham operation group, p < 0.01.
[0057] 3.2 Balance beam test results: The results are shown in Table 2. 24 hours after surgery, the balance beam passing time of the rats in the sham operation group was 7.89±0.93s; the balance beam passing time of the rats in the model group was 60.00±0.00s. Compared with the sham operation group, there was a statistically significant difference (p<0.01); the balance beam passing time of the rats in the high-dose bremelanotide group was 39.05±11.71s; the balance beam passing time of the rats in the low-dose bremelanotide group was 44.60±11.51s; compared with the model group, both the high-dose bremelanotide group and the low-dose bremelanotide group showed statistically significant differences (p<0.01).
[0058] 48 hours after surgery, the balance beam passing time of rats in the sham operation group was 9.27±1.64s; the balance beam passing time of rats in the model group was 60.00±0.00s. Compared with the sham operation group, there was a statistically significant difference (p<0.01); the balance beam passing time of rats in the high-dose bremelanotide group was 43.96±14.02s; the balance beam passing time of rats in the low-dose bremelanotide group was 43.45±12.32s; compared with the model group, both the high-dose bremelanotide group and the low-dose bremelanotide group showed statistically significant differences (p<0.01).
[0059] Table 2 Effects of bremelanotide on balance beam in stroke rats (n=10)
[0060]
[0061] Note: ## Indicates p < 0.01 compared with the sham operation group; ** Indicates comparison with the model group, p < 0.01.
[0062] 3.3 Grip strength test results: The results are shown in Table 3. 24 hours after surgery, the grip strength of rats in the sham group was 677.42±45.03g; the grip strength of rats in the model group was 414.02±26.56g. Compared with the sham group, there was a statistically significant difference (p<0.01); the grip strength of rats in the high-dose bremelanotide group was 512.90±30.78g; the grip strength of rats in the low-dose bremelanotide group was 489.38±44.85g; compared with the model group, both the high-dose bremelanotide group and the low-dose bremelanotide group showed statistically significant differences (p<0.01).
[0063] 48 hours after surgery, the grip strength of rats in the sham group was 692.84±51.82g; the grip strength of rats in the model group was 412.33±21.25g. Compared with the sham group, there was a statistically significant difference (p<0.01); the grip strength of rats in the high-dose bremelanotide group was 508.71±37.39g; the grip strength of rats in the low-dose bremelanotide group was 474.60±50.26g; compared with the model group, both the high-dose bremelanotide group and the low-dose bremelanotide group showed statistically significant differences (p<0.01).
[0064] Table 3 Effects of bremelanotide on grip strength of stroke rats (n=10)
[0065]
[0066] Note: ## Indicates p < 0.01 compared with the sham operation group; ** Indicates comparison with the model group, p < 0.01.
[0067] 3.4 Rotarod test results: The results are shown in Table 4. 24 hours after surgery, the rotarod retention time of rats in the sham operation group was 298.80±3.79s; the rotarod retention time of rats in the model group was 52.90±16.62s. Compared with the sham operation group, there was a statistically significant difference (p<0.01); the rotarod retention time of rats in the high-dose bremelanotide group was 79.56±23.70s; the rotarod retention time of rats in the low-dose bremelanotide group was 82.33±48.84s; compared with the model group, the high-dose bremelanotide group showed a statistically significant difference (p<0.05).
[0068] 48 hours after surgery, the rotarod retention time of rats in the sham operation group was 293.50±20.55s; the rotarod retention time of rats in the model group was 63.30±25.49s. Compared with the sham operation group, there was a statistically significant difference (p<0.01); the rotarod retention time of rats in the high-dose bremelanotide group was 100.22±57.33s; the rotarod retention time of rats in the low-dose bremelanotide group was 96.00±48.48s.
[0069] Table 4 Effects of bremelanotide on rotarod in stroke rats (n=10)
[0070]
[0071] Note: ## Indicates p < 0.01 compared with the sham operation group; * Indicates comparison with the model group, p < 0.05.
[0072] 3.5 Changes in cerebral blood flow: 10 minutes after surgery, Doppler cerebral blood flow observations of rats in the sham operation group, model group, high-dose bremelanotide group, and low-dose bremelanotide group were as follows: Figure 1 The results of cerebral blood flow changes are shown in Table 5. As shown in Table 5, 10 minutes after surgery (no medication), the difference in left and right cerebral blood flow in rats in the sham operation group was 0.48±0.27%; the difference in cerebral blood flow in rats in the model group was 57.12±2.00%. Compared with the sham operation group, there was a statistically significant difference (p<0.01); the difference in cerebral blood flow in rats in the high-dose bremelanotide group was 55.76±2.17%; the difference in cerebral blood flow in rats in the low-dose bremelanotide group was 56.02±2.05%.
[0073] 24 hours after surgery, Doppler cerebral blood flow observation images of rats in the sham operation group, model group, high-dose bremelanotide group and low-dose bremelanotide group are shown in Figure 2. Figure 2 As shown. 24 hours after surgery, the cerebral blood flow difference of rats in the sham operation group was 0.44±0.20%; the cerebral blood flow difference of rats in the model group was 27.98±14.97%. Compared with the sham operation group, there was a statistically significant difference (p<0.01); the cerebral blood flow difference of rats in the high-dose bremelanotide group was 19.06±8.81%; the cerebral blood flow difference of rats in the low-dose bremelanotide group was 19.42±18.14%.
[0074] At 48 hours after surgery, Doppler cerebral blood flow observation images of rats in the sham operation group, model group, high-dose bremelanotide group, and low-dose bremelanotide group were shown in Figure 2. Figure 3As shown. 48h after surgery, the cerebral blood flow difference of rats in the sham operation group was 0.43±0.26%; the cerebral blood flow difference of rats in the model group was 29.49±11.74%. Compared with the sham operation group, there was a statistically significant difference (p<0.01); the cerebral blood flow difference of rats in the high-dose bremelanotide group was 23.70±10.94%; the cerebral blood flow difference of rats in the low-dose bremelanotide group was 26.77±12.12%.
[0075] Table 5 Effects of bremelanotide on cerebral blood flow in stroke rats (n=10)
[0076]
[0077] Note: ## Compared with the sham operation group, p < 0.01.
[0078] 3.6 Brain volume and cerebral infarction area test results: The brain volume results are shown in Table 6. The brain volume of rats in the sham operation group was 1.467±0.04mL; the brain volume of rats in the model group was 1.667±0.09mL. Compared with the sham operation group, there was a statistically significant difference (p<0.01); the brain volume of rats in the high-dose bremelanotide group was 1.650±0.13mL; the brain volume of rats in the low-dose bremelanotide group was 1.676±0.08mL.
[0079] Table 6 Effects of bremelanotide on brain volume in stroke rats (n=10)
[0080] Group Brain volume (mL) Sham operation group 1.467±0.04 Model Group <![CDATA[1.667±0.09 ## ]]> High-dose bremelanotide 1.650±0.13 Low-dose bremelanotide 1.676±0.08
[0081] Note: ## Compared with the sham operation group, p < 0.01.
[0082] The results of the cerebral infarction area test are as follows Figure 4-6 As shown, Figure 4 This is the TTC staining picture of the brain sections of the rats in the sham operation group. Figure 5 This is the TTC staining picture of the brain sections of rats in the model group. Figure 6 This is the TTC staining image of the brain sections of rats in the high-dose group of bremelanotide. It can be seen that cerebral infarction was significantly improved, and the improvement rate of infarct area exceeded 30%.
[0083] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.
Claims
1. Use of bremelanotide in the preparation of drugs for preventing and / or treating ischemic stroke.
2. The use according to claim 1, characterized in that: Use of bremelanotide in the preparation of drugs for improving neurological deficits.
3. The use according to claim 1, characterized in that: Application of bremelanotide in the preparation of drugs for reducing the area of cerebral infarction.
4. The use according to claim 1, characterized in that: Use of bremelanotide in the preparation of drugs for improving cerebral blood flow in ischemic stroke.
5. The use according to any one of claims 1 to 4, characterized in that: Bremelanotide is the only active ingredient in the drug.
6. The use according to claim 1, characterized in that: The drug also includes pharmaceutically acceptable excipients.
7. The use according to claim 6, characterized in that: The auxiliary materials include one or more of surfactants, buffer substances, disintegrants, binders, fillers, lubricants, solubilizers, flavoring agents and colorants.
8. The use according to claim 1, characterized in that: The dosage form of the drug includes oral dosage form and parenteral dosage form.
9. The use according to claim 8, characterized in that: The oral dosage form is tablets, capsules, granules, granules, pills, oral liquid preparations, gel preparations or freeze-dried powder injections.
10. The use according to claim 8, characterized in that: The non-intestinal administration dosage form is an injection dosage form, a respiratory tract administration dosage form, a skin administration dosage form, a mucosal administration dosage form or a cavity administration dosage form.
Citation Information
Patent Citations
Bremelanotide oral pharmaceutical composition bremelanotide and application thereof
CN112587651A
Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications
US20230040236A1
Treatment of medical indication
US20230101963A1
Cited By
Use of bremelanotide in preparation of drug for treating ischemic stroke
WO2026045135A1
